These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 34045081)

  • 1. Clinical outcomes of ceftazidime-avibactam versus meropenem in Indian patients with nosocomial pneumonia: Subset analysis from the REPROVE study.
    Sathe P; Kamat S; Adhav C
    Indian J Med Microbiol; 2021 Jul; 39(3):363-366. PubMed ID: 34045081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
    Torres A; Zhong N; Pachl J; Timsit JF; Kollef M; Chen Z; Song J; Taylor D; Laud PJ; Stone GG; Chow JW
    Lancet Infect Dis; 2018 Mar; 18(3):285-295. PubMed ID: 29254862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
    Tichy E; Torres A; Bassetti M; Kongnakorn T; Di Virgilio R; Irani P; Charbonneau C
    Clin Ther; 2020 May; 42(5):802-817. PubMed ID: 32349879
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Stone GG; Bradford PA; Tawadrous M; Taylor D; Cadatal MJ; Chen Z; Chow JW
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
    Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
    J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.
    Das S; Zhou D; Nichols WW; Townsend A; Newell P; Li J
    Eur J Clin Pharmacol; 2020 Mar; 76(3):349-361. PubMed ID: 31836928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM.
    Rodgers P; Kamat S; Adhav C
    J Infect Dev Ctries; 2022 Feb; 16(2):305-313. PubMed ID: 35298426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points.
    Torres A; Rank D; Melnick D; Rekeda L; Chen X; Riccobene T; Critchley IA; Lakkis HD; Taylor D; Talley AK
    Open Forum Infect Dis; 2019 Apr; 6(4):ofz149. PubMed ID: 31041348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
    Zhong H; Zhao XY; Zhang ZL; Gu ZC; Zhang C; Gao Y; Cui M
    Int J Antimicrob Agents; 2018 Oct; 52(4):443-450. PubMed ID: 30012440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
    Qin X; Tran BG; Kim MJ; Wang L; Nguyen DA; Chen Q; Song J; Laud PJ; Stone GG; Chow JW
    Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
    Sy SKB; Zhuang L; Sy S; Derendorf H
    Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
    Bradley JS; Broadhurst H; Cheng K; Mendez M; Newell P; Prchlik M; Stone GG; Talley AK; Tawadrous M; Wajsbrot D; Yates K; Zuzova A; Gardner A
    Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
    Varón-Vega FA; Lemos E; Castaño GN; Reyes JM
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):235-240. PubMed ID: 34407710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
    Stone GG; Seifert H; Nord CE
    Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.